TetraPhase Pharmaceuticals Presents Data at ECCMID from Growing Portfolio of Next-Generation Antibiotic Candidates  
4/2/2012 10:21:45 AM

WATERTOWN, Mass.--(BUSINESS WIRE)--Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on next-generation antibiotics, announced today that it is presenting new results from studies that demonstrate the improved potency and pharmacokinetics of several of its newest discovery-stage tetracycline analogs. These data, which focus on significant gram-negative pathogens – including Pseudomonas aeruginosa, and troublesome gram-positive respiratory pathogens – were described in seven poster presentations at the 22nd European Congress of Clinical Microbiology and Infectious Disease (ECCMID) in London, UK.